Aprepitant  别名:MK-0869, L-754030, Emend; 阿瑞匹坦

目录号 M1650

Aprepitant(阿瑞匹坦)是一种口服活性且高亲和力的神经激肽1(NK-1)受体拮抗剂,其Kd 值为86 pM。

Aprepitant结构式

  CAS No.:170729-80-3

规格 价格 库存状态
Free Sample (0.5-1 mg)  ¥ 0 现货
10mM*1mL ¥ 630 现货
1mg ¥ 225 现货
5mg ¥ 495 现货
10mg ¥ 720 现货
50mg ¥ 2700 现货
100mg ¥ 3960 现货
*AbMole所有产品仅供有资质的科研机构或医药企业进行科学研究或药证申报用途,不能被用于人体和任何其它用途。我们不向任何个人或非科研性质的机构提供产品和服务。
质量标准及产品资料
化学性质/溶解性/储存
分子量 534.43
分子式 C23H21F7N4O3
CAS号 170729-80-3
中文名称 阿瑞匹坦
溶解性 DMSO 90 mg/mL
储存条件 2-8°C, protect from light
运输方式 冰袋运输,根据产品的不同,可能会有相应调整。
生物活性
Aprepitant(阿瑞匹坦)是一种口服活性且高亲和力的神经激肽1(NK-1)受体拮抗剂,其Kd 值为86 pM。
实验参考
蛋白/细胞实验

下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。

浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 1.8712 mL 9.3558 mL 18.7115 mL
5 mM 0.3742 mL 1.8712 mL 3.7423 mL
10 mM 0.1871 mL 0.9356 mL 1.8712 mL

*吸湿的DMSO对产品的溶解度有显著影响,请使用新开封的DMSO;
 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。


质量   浓度   体积   分子量*
 =   x   x 

细胞系 human CAPAN pancreas, HEp-2 larynx, gastric 23132-87 and SW-403 colon carcinoma cells
方法 Proliferation assays.
Cell proliferation was evaluated using the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS), according to the manufacturer’s instructions (CellTiter 96 Aqueous One Solution Cell Proliferation Assay). Cell numbers were quantified using a Coulter counter. Cells were cultured in 96-well plates: each well contained 104 cells in a total volume of 100 µl. Each assay included one plate The plate included blank wells (0 cells/0.1 ml), control wells (104 cells /0.1 ml), control wells with acetonitrylo, control wells treated with aprepitant and control wells treated with the most effective SP concentration and aprepitant. The plates were inoculated with aprepitant (5–70 µM for tumor cell lines) and were incubated for the first doubling time specific for each tumor cell line. The plates were also inoculated the most mitogenic exogenous SP nM concentration with the fifty-percent inhibition concentration (IC50) of aprepitant µM concentration approximately and without aprepitant for their first doubling times respectively. For the proliferation assay, 20 µl of the MTS reagent was added to each well 90 min before reading the samples on a multiscanner microplate reader (TECAN Spectra classic, Barcelona, Spain) at 492 nm. The quantity of product, as measured by optical density, is directly proportional to the number of living cells.
浓度 5-70 µM
处理时间 2 days

* 上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。

动物实验

建议您制定动物给药及实验方案时,尽量参考已发表的相关实验文献(溶剂种类及配比众多,简单地溶解目的化合物,并不能解决动物给药依从性、体内生物利用度、组织分布等相关问题,未必能保证目的化合物在动物体内充分发挥生物学效用)。
体内实验的工作液,建议您现用现配,当天使用;如在配制过程中出现沉淀、析出现象,可以通过超声和(或)加热的方式助溶。
切勿一次性将产品全部溶解。


动物实验方案计算器

请在下面的计算器中,输入您的动物实验相关数据并点击计算,即可得到该实验的总需药量和工作液终浓度。
例如您给药剂量是10 mg/kg,平均每只动物的体重为20 g,每只动物的给药体积是100 μL,动物数量为20只,则该动物实验的总需药量为4 mg,工作液终浓度为2 mg/mL。

mg/kg
uL
该动物实验的总需药量为 mg
工作液终浓度2 mg/mL

1:鉴于实验过程的损耗,建议您至少多配1-2只动物的量;
2:为该产品最终给药时的浓度。


动物模型 acute cisplatin-induced emesis in ferrets
配制 Methocel or PEG 300
剂量 0.3, 1, 3mg/kg
给药处理 p.o. or i.v.

* 上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。

参考文献

[1] Albany et al. J Clin Oncol. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

[2] Stiff et al. Biol Blood Marrow Transplant. Prevention of Nausea and Vomiting Associated with Stem Cell Transplantation: Results of a Prospective, Randomized Trial of Aprepitant used with Highly Emetogenic Preparative Regimens.

[3] Bergese et al. Trials. Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial.

[4] Green et al. Br J Anaesth. Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant and transdermal scopolamine for prevention of postoperative nausea and vomiting.

[5] Longo et al. Int J Clin Pract. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

[6] Munoz M, et al. Invest New Drugs. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

[7] Tattersall FD, et al. Neuropharmacology. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.






关键词:Aprepitant, MK-0869, L-754030, Emend, Aprepitant供应商, Neurokinin Receptor抑制剂, 购买Aprepitant, Aprepitant溶解度, Aprepitant结构式







产品仅供科学研究或药证申报的用途使用,不为任何个人或者非科研性质的其他用途提供服务。

Copyright © 2010-2025 AbMole版权所有